|Bid||0.00 x 1400|
|Ask||0.00 x 800|
|Day's Range||3.2600 - 3.4800|
|52 Week Range||1.1500 - 28.6940|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.00|
NEW YORK , Jan. 5, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...
NEW YORK, NY / ACCESSWIRE / December 3, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Arsanis, Inc. (ASNS), a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases. Arsanis' pipeline is comprised of mAbs targeting multiple serious bacterial and viral pathogens, including a respiratory syncytial virus. A merger announcement involving ASNS sent the company shares soaring from $1.16 on November 26, 2018 to $4.12 per share the next day.
HENDERSON, NV / ACCESSWIRE / November 29, 2018 / Here are a few biotech/ healthcare and CBD companies that require your attention. Today we are highlighting: BioRestorative Therapies, Inc. (BRTX), MedMen ...
Clinical-stage biopharma Arsanis, Inc. (NASDAQ: ASNS) conducts research and develops applications for monoclonal antibody immunotherapies. Arsanis announced its entrance into a definitive merger agreement with X4 Pharmaceuticals in a Wednesday press release. X4 Pharmaceuticals will merge with a subsidiary of Arsanis through an all-stock transaction.
NEW YORK, NY / ACCESSWIRE / November 28, 2018 / Biotech stocks Arsanis and Aethlon Medical were both seeing big gains on Tuesday on positive developments. Arsanis and privately held X4 Pharmaceuticals have agreed to merge and Aethlon announced it had received Breakthrough Device designation from FDA for their Hemopurifier in the treatment of cancer.
Just a few months after shelving its sole clinical trial and laying off nearly half of its workforce, Waltham's Arsanis Inc. announced it will be absorbed by Cambridge's X4 Pharmaceuticals in a reverse merger that could bring more layoffs.
NEW YORK, NY / ACCESSWIRE / November 27, 2018 / WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Arsanis, Inc. ("ASNS" ...
CORAL GABLES, FL / ACCESSWIRE / November 27, 2018 / Healthcare stocks helped boost the stock market rally on Monday. Recently concluded mid-term elections have provided a much-needed boost to the healthcare sector. New trends that the majority of healthcare companies are working on are also boosting the sector.
Arsanis, Inc. (ASNS) and privately-held X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics designed to improve immune cell trafficking to treat rare diseases and cancer, today announced that they have entered into a definitive merger agreement under which X4 Pharmaceuticals is expected to merge with a wholly-owned subsidiary of Arsanis in an all-stock transaction. “X4 has pioneered the development of novel, oral drug candidates targeting pathways that have been demonstrated to improve immune cell trafficking and restore healthy immunity in genetically-driven rare diseases and lymphomas.
WALTHAM, Mass. and VIENNA, Austria, Nov. 09, 2018 -- Arsanis, Inc. (NASDAQ: ASNS), a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb).
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 13) Iradimed Corp (NASDAQ: IRMD ) SurModics, Inc. (NASDAQ: SRDX ...
Holzer & Holzer, LLC is investigating whether Arsanis, Inc. (“Arsanis” or the “Company”) (ASNS) complied with the federal securities laws. On June 28, 2018, Arsanis announced the discontinuation of its Phase 2 clinical trial of ASN100, a preventive drug for mechanically ventilated patients with a high risk of contracting pneumonia. Arsanis disclosed that an analysis completed by an independent drug review committee found that continuing the trial was “futile” because the target primary end-point likely would not be met upon completion. If you purchased Arsanis common stock and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq.
Arsanis, Inc. , a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, today reported business highlights and financial results for the first quarter ended March 31, 2018.
71 Abstracts to be Presented by Coalition Members During the Annual Meeting WASHINGTON , April 20, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) today announced that thirteen of its member ...
Arsanis, Inc. , a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, announced today that the company will present five scientific posters at the 28th European Congress of Clinical Microbiology and Infectious Diseases in Madrid, Spain from April 21 – 24, 2018. The posters will highlight new research findings and supportive ...